Israeli scientists have successfully grown powerful adult stem cells from those circulating in the blood and returned them to revitalise the hearts of ailing patients.
The details of the clinical trial will be announced at the American Heart Association Scientific Meeting in Chicago later this week. The results give new hope to seriously ill heart patients.
Members of the AHA will be given an abstract of clinical trial results that conclusively demonstrate the efficacy of adult stem cell treatment for end stage cardiac patients.
TheraVitae, the acknowledged leader in stem cell research and development is to present recently concluded trial results that provide dramatic data revealing the improvement in the lives of seriously ill patients.
The founder of Theravitae, Don Margolis, said that a mere half pint of each patient’s blood was extracted in Bangkok and flown to their laboratory in Israel. There, the few adult stem cells were harvested into millions of such cells. A week later those infinitely more powerful cells were injected non-surgically into the patient’s cardio-vascular system.
Standard cardiac measurements and the patients’ own words give eloquent testimony to the positive outcomes of harvesting stem cells from these seriously ill cardiac patients.
Margolis is upbeat that patients can receive the best hospital care available anywhere in the world and a significant number can then return to a new, more normal and healthy life. These findings give new hope to sufferers via clinically proven mainstream medical methods.
About VesCell – A Natural Treatment for Heart Disease
The body has natural ways of healing itself and the cardiovascular system is no exception. Angiogenic Cell Precursors (ACPs) originate in bone marrow and then circulate in the blood vessels. To manufacture VesCell, TheraVitae expands a small number of ACPs harvested from about 250cc of blood into a therapeutic quantity. VesCell is injected either through a coronary artery via catheter, or during surgery, directly into the heart muscle.
A key aspect of VesCell therapy is the advanced cell isolation and expansion technique that allows for the ACPs to be harvested from blood collected in a procedure similar to a common blood donation. VesCell uses a patient’s own adult stem cells to treat Heart Disease and is a viable therapeutic possibility for heart patients without any other treatment option.
Additional Information on Stem Cell Therapy:
TheraVitae is a private, multinational company focused on using stem cells from the patient’s own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has already developed a proprietary stem cell technology ‘VesCell’ that is currently being used by hospitals in Thailand to treat patients with Heart Disease. TheraVitae is based in Bangkok, Thailand, Kiryat Weizmann, Israel, Toronto, Canada, Singapore, Taipei, Taiwan and Hong Kong.
TheraVitae Corporate Website: www.theravitae.com
36/72 PS Tower, 21/Fl., Sukhumvit 21
Klongtoey Nua, Bangkok 10110
7 Pinhas Sapir Street
P.O. Box 4049, Ness Ziona